《人類基因治療》是一本涵蓋基因治療各個方面的多學科雜志。該雜志通過提供最新的研究和技術突破，對DNA、RNA和細胞療法進行了深入報道。人類基因治療為科學和臨床信息提供了一個中心論壇，包括倫理、法律、監管、社會和商業問題，使治療程序的進步和進步能夠改善患者的結果，并最終治愈疾病。該期刊分為三個部分。人類基因療法是其旗艦，每年出版12期。《HGT Methods》是一本雙月刊，主要研究基因治療在產品檢測和開發中的應用。HGT臨床發展是一份季刊，作為發布與細胞和基因治療產品的監管審查和商業開發相關的數據的場所。完整的覆蓋范圍包括:向量發展的改善運載系統細胞療法小型核酸療法，包括RNAi臨床試驗和動物模型臨床協議臨床前動物和體外研究評估用于支持臨床應用的基因和細胞治療產品的安全性臨床試驗，包括結果證實性或陰性的臨床試驗與基因和細胞治療產品的商業開發相關的熱點問題

Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.Complete coverage includes: Improvements in vector developments Delivery systems Cell therapy Small nucleic acid therapeutics, including RNAi Clinical trials and animal models Clinical protocols Pre-clinical animal and in vitro studies to assess the safety of gene and cell therapy products used to support clinical applications Clinical trials including those in which the results are confirmatory or negative Topical issues related to the commercial development of gene and cell therapy products